tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RARE Stock Latest News

Buy Rating on Ultragenyx Pharmaceutical: Promising Potential of Setrusumab for Osteogenesis Imperfecta and Attractive Risk/Reward Profile
RatingsBuy Rating on Ultragenyx Pharmaceutical: Promising Potential of Setrusumab for Osteogenesis Imperfecta and Attractive Risk/Reward Profile
11d ago
RARE
Centrus, BWX, Ultragenyx, Macy’s, TripAdvisor: Trending by Analysts
PremiumWeekend Updates
Centrus, BWX, Ultragenyx, Macy’s, TripAdvisor: Trending by Analysts
22d ago
M
LEU
Ultragenyx initiated with an Outperform at William Blair
PremiumThe Fly
Ultragenyx initiated with an Outperform at William Blair
25d ago
RARE
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting
1M ago
8K
RARE
Optimistic Buy Rating for Ultragenyx: Strategic Developments and Favorable Regulatory Landscape Drive Growth Prospects
PremiumRatings
Optimistic Buy Rating for Ultragenyx: Strategic Developments and Favorable Regulatory Landscape Drive Growth Prospects
1M ago
RARE
Ultragenyx Pharmaceutical: Promising Growth and Strategic Milestones Reinforce Buy Rating
PremiumRatingsUltragenyx Pharmaceutical: Promising Growth and Strategic Milestones Reinforce Buy Rating
1M ago
RARE
Ultragenyx Reports Strong Growth Amid Challenges
Premium
Company Announcements
Ultragenyx Reports Strong Growth Amid Challenges
2M ago
RARE
Ultragenyx price target lowered to $100 from $140 at Truist
Premium
The Fly
Ultragenyx price target lowered to $100 from $140 at Truist
2M ago
RARE
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand
PremiumRatings
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand
2M ago
RARE
Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point
PremiumRatings
Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point
2M ago
RARE
Investors will be rewarded for buying Ultragenyx at $35, says Citi
PremiumThe Fly
Investors will be rewarded for buying Ultragenyx at $35, says Citi
2M ago
RARE
Buy Recommendation for Ultragenyx Pharmaceutical Driven by Strong Commercial Execution and Promising Pipeline
PremiumRatings
Buy Recommendation for Ultragenyx Pharmaceutical Driven by Strong Commercial Execution and Promising Pipeline
2M ago
RARE
Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating
PremiumRatingsUltragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating
2M ago
RARE
Ultragenyx Reports Strong Q1 2025 Revenue Growth
Premium
Company Announcements
Ultragenyx Reports Strong Q1 2025 Revenue Growth
2M ago
RARE
Ultragenyx reports Q1 EPS ($1.57), consensus ($1.64)
Premium
The Fly
Ultragenyx reports Q1 EPS ($1.57), consensus ($1.64)
2M ago
RARE
Ultragenyx reaffirms FY25 revenue view of $640M-$670M, consensus $655.81M
PremiumThe Fly
Ultragenyx reaffirms FY25 revenue view of $640M-$670M, consensus $655.81M
2M ago
RARE
Controversial doctor Vinay Prasad named CBER director, STAT reports
PremiumThe Fly
Controversial doctor Vinay Prasad named CBER director, STAT reports
2M ago
DYN
RNA
RARE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RARE Upcoming Earnings Report: What to Expect?
2M ago
RARE
RBC sees Makary interview as potentially positive for biotech stocks
PremiumThe Fly
RBC sees Makary interview as potentially positive for biotech stocks
2M ago
DYN
RNA
Ultragenyx price target lowered to $80 from $83 at BofA
PremiumThe FlyUltragenyx price target lowered to $80 from $83 at BofA
2M ago
RARE
Ultragenyx price target raised to $117 from $104 at JPMorgan
Premium
The Fly
Ultragenyx price target raised to $117 from $104 at JPMorgan
3M ago
RARE
Rezolute appoints Erik Harris to board of directors
Premium
The Fly
Rezolute appoints Erik Harris to board of directors
3M ago
RARE
RZLT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >